Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Vertex Pharmaceuticals exec sells shares worth $803,323
Edward Morrow Atkinson III, Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently sold a significant portion of his holdings in the ...
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Vertex wins FDA approval for long-awaited non-opioid painkiller
Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Healthcare Dive1d
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
manilatimes1d
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...